GC012F

GC012F is a CAR-T cell therapy developed by Gracell Biotechnologies (Shanghai). Its targets are CD19 and BCMA (the sponsor names BCMA x CD19). The sponsor states: A dual chimeric antigen receptor (CAR) T-cell product engineered to recognise and attack multiple myeloma cells expressing either BCMA or CD19. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT06235229, plans to enrol 110 participants with primary completion expected 2026-03-02. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.